---
title: "XOMA Corp Pref Share 8.625 Perp 12/15/21 | 8-K: FY2025 Q2 Revenue: USD 13.13 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/252853961.md"
datetime: "2025-08-13T11:46:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/252853961.md)
  - [en](https://longbridge.com/en/news/252853961.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/252853961.md)
---

# XOMA Corp Pref Share 8.625 Perp 12/15/21 | 8-K: FY2025 Q2 Revenue: USD 13.13 M

Revenue: As of FY2025 Q2, the actual value is USD 13.13 M.

EPS: As of FY2025 Q2, the actual value is USD 0.44.

### Segment Revenue

-   XOMA Royalty received $29.6 million in cash from partners in the first half of 2025, with $16.0 million from royalty payments related to commercial sales and $13.6 million from milestone payments and fees.

### Operational Metrics

-   Net income for the three and six months ended June 30, 2025, was $9.2 million and $11.6 million, respectively, compared to $16.0 million and $7.4 million for the corresponding periods of 2024.
-   General and Administrative (G&A) expenses for the three and six months ended June 30, 2025, were $7.8 million and $15.9 million, respectively, compared to $11.0 million and $19.5 million for the corresponding periods of 2024.

### Cash Flow

-   Net cash provided by operating activities was $8.7 million for the six months ended June 30, 2025.
-   Net cash used in investing activities was - $26.7 million for the six months ended June 30, 2025.
-   Net cash used in financing activities was - $9.9 million for the six months ended June 30, 2025.

### Unique Metrics

-   XOMA Royalty deployed $20 million to acquire additional economics in mezagitamab and repurchased approximately 81,700 shares of its common stock for a cost of $1.8 million during the second quarter of 2025.

### Outlook / Guidance

-   XOMA Royalty anticipates becoming cash flow positive on a consistent basis exclusively from cash payments received from royalties as new commercial opportunities emerge within its portfolio.

### Related Stocks

- [XOMAP.US](https://longbridge.com/en/quote/XOMAP.US.md)

## Related News & Research

- [Meet the Dividend King That's Quietly Crushing the S&P 500 in 2026. Here's Why It's a Buy This August.](https://longbridge.com/en/news/296262501.md)
- [Warren Buffett's Successor, Greg Abel, Has 34.7% of Berkshire Hathaway's Portfolio Invested in These 2 Artificial Intelligence (AI) Stocks](https://longbridge.com/en/news/296274565.md)
- [Oil edges up on uncertainty over exports through Hormuz](https://longbridge.com/en/news/296282399.md)
- [ANET, SPOT, HOOD: 3 Best Growth Stocks to Buy This Week, According to Analysts](https://longbridge.com/en/news/296275933.md)
- [As retail stagnates, ad dollars help Walmart stay the course](https://longbridge.com/en/news/296209943.md)